Jr. Michael Conick Hanley - 08 Jun 2022 Form 4 Insider Report for Aeglea BioTherapeutics, Inc. (SYRE)

Role
Chief Commercial Officer
Signature
/s/ James Kastenmayer, by power of attorney
Issuer symbol
SYRE
Transactions as of
08 Jun 2022
Net transactions value
+$20,022
Form type
4
Filing time
10 Jun 2022, 18:24:26 UTC
Previous filing
22 Feb 2022
Next filing
25 Aug 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGLE Common Stock Purchase $20,022 +28,200 +352% $0.7100 36,200 08 Jun 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 8,000 shares of common stock acquired by the Reporting Person pursuant to the Issuer's employee stock purchase plan.